These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31742892)

  • 1. Systematic screening identifies a 2-gene signature as a high-potential prognostic marker of undifferentiated pleomorphic sarcoma/myxofibrosarcoma.
    Hu Q; Zhou S; Hu X; Zhang H; Huang S; Wang Y
    J Cell Mol Med; 2020 Jan; 24(1):1010-1021. PubMed ID: 31742892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
    Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
    Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review.
    Yoshimoto M; Yamada Y; Ishihara S; Kohashi K; Toda Y; Ito Y; Yamamoto H; Furue M; Nakashima Y; Oda Y
    Am J Surg Pathol; 2020 Jan; 44(1):87-97. PubMed ID: 31651522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
    Lee AY; Agaram NP; Qin LX; Kuk D; Curtin C; Brennan MF; Singer S
    Ann Surg Oncol; 2016 Mar; 23(3):818-25. PubMed ID: 26759307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma.
    Shen R; Liu B; Li X; Yu T; Xu K; Ma J
    BMC Cancer; 2021 Feb; 21(1):144. PubMed ID: 33557781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
    Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
    Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.
    Conley AP; Wang WL; Livingston JA; Ravi V; Tsai JW; Ali A; Ingram DR; Lowery CD; Roland CL; Somaiah N; Hwu P; Yee C; Subbiah V; Futreal A; Lazar AJ; Patel S; Roszik J
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31096717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.
    Okada T; Lee AY; Qin LX; Agaram N; Mimae T; Shen Y; O'Connor R; López-Lago MA; Craig A; Miller ML; Agius P; Molinelli E; Socci ND; Crago AM; Shima F; Sander C; Singer S
    Cancer Discov; 2016 Oct; 6(10):1148-1165. PubMed ID: 27577794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma.
    Iwata S; Yonemoto T; Araki A; Ikebe D; Kamoda H; Hagiwara Y; Ishii T
    J Surg Oncol; 2014 Nov; 110(6):707-11. PubMed ID: 24975462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma.
    Piano MA; Brunello A; Cappellesso R; Del Bianco P; Mattiolo A; Fritegotto C; Montini B; Zamuner C; Del Fiore P; Rastrelli M; Sommariva A; De Salvo GL; Montesco MC; Rossi CR; Zagonel V; Calabrò ML
    Clin Cancer Res; 2020 Jun; 26(12):2921-2931. PubMed ID: 32127392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LMX1B mRNA expression and its gene body CpG methylation are valuable prognostic biomarkers for laryngeal squamous cell carcinoma.
    Fan L; Zhang A; Deng P
    Biomed Pharmacother; 2019 Sep; 117():109174. PubMed ID: 31387183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OSmfs: An Online Interactive Tool to Evaluate Prognostic Markers for Myxofibrosarcoma.
    Li H; Xie L; Wang Q; Dang Y; Sun X; Zhang L; Han Y; Yan Z; Dong H; Zheng H; Li Y; Zhu W; Guo X
    Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33352742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
    Crago AM; Cardona K; Koseła-Paterczyk H; Rutkowski P
    Surg Oncol Clin N Am; 2022 Jul; 31(3):419-430. PubMed ID: 35715142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.
    Widemann BC; Italiano A
    J Clin Oncol; 2018 Jan; 36(2):160-167. PubMed ID: 29220302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors and Outcomes for Patients With Myxofibrosarcoma: A 13-Year Retrospective Evaluation.
    Mühlhofer HML; Lenze U; Gersing A; Lallinger V; Burgkart R; Obermeier A; VON Eisenhart-Rothe R; Knebel C
    Anticancer Res; 2019 Jun; 39(6):2985-2992. PubMed ID: 31177139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
    Zhang B; Yang L; Wang X; Fu D
    Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Biology of Myxofibrosarcoma: State of the Art and Future Perspectives.
    Sambri A; De Paolis M; Spinnato P; Donati DM; Bianchi G
    Oncol Res Treat; 2020; 43(6):314-322. PubMed ID: 32450554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical margins do not affect prognosis in high grade myxofibrosarcoma.
    Sambri A; Bianchi G; Righi A; Ferrari C; Donati D
    Eur J Surg Oncol; 2016 Jul; 42(7):1042-8. PubMed ID: 27260849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
    Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
    Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.